| 參考文獻 |
Babapoor, S., M. Horwich, R. Wu, S. Levinson, M. Gandhi, H. Makkar, A. Kristjansson, M. Chang and S. S. Dadras (2016). "microRNA in situ hybridization for miR-211 detection as an ancillary test in melanoma diagnosis." Mod Pathol 29(5): 461-475.
Bartels, C. L. and G. J. Tsongalis (2009). "MicroRNAs: novel biomarkers for human cancer." Clin Chem 55(4): 623-631.
Bishop, P. W., L. P. Menasce, A. J. Yates, N. A. Win and S. S. Banerjee (1993). "An immunophenotypic survey of malignant melanomas." Histopathology 23(2): 159-166.
Bradford, P. T., A. M. Goldstein, M. L. McMaster and M. A. Tucker (2009). "Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005." Arch Dermatol 145(4): 427-434.
Busam, K. J., Y. T. Chen, L. J. Old, E. Stockert, K. Iversen, K. A. Coplan, J. Rosai, R. L. Barnhill and A. A. Jungbluth (1998). "Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma." Am J Surg Pathol 22(8): 976-982.
Busam, K. J., D. Kucukgol, E. Sato, D. Frosina, J. Teruya-Feldstein and A. A. Jungbluth (2005). "Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers." Am J Surg Pathol 29(3): 400-406.
Chen, Q., C. Xia, Y. Deng, M. Wang, P. Luo, C. Wu, J. Yue, N. Fang, M. Wang and S. Wei (2014). "Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients." Tumour Biol 35(6): 5727-5733.
Chakraborty, S., A. K. Ganti, A. Marr and S. K. Batra (2010). "Lung cancer in women: role of estrogens." Expert Rev Respir Med 4(4): 509-518.
Chang, J. W.-C. (2010). "Cutaneous Melanoma: Taiwan Experience and Literature Review." Chang Gung Med J Am Acad Dermatol 33: 602-612.
Chorny, J. A., R. J. Barr, A. Kyshtoobayeva, J. Jakowatz and R. J. Reed (2003). "Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions." Mod Pathol 16(6): 525-529.
Christopher J. Hussussian, J. P. S., Alisa M. Goldstein, Paul A. T. Higgins, Delphine S. Ally, Michelle D. Sheahan1, Wallace H. Clark Jr., Margaret A. Tucker & Nicholas C. Dracopoli, (1994). "Germline p16 mutations in familial melanoma." Nature Genetics 8: 15-21.
Clarkson, K. S., I. C. Sturdgess and A. J. Molyneux (2001). "The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A)." J Clin Pathol 54(3): 196-200.
Cochran, A. J. and D. R. Wen (1985). "S-100 protein as a marker for melanocytic and other tumours." Pathology 17(2): 340-345.
Compton, L. A., G. F. Murphy and C. G. Lian (2015). "Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update." Dermatopathology (Basel) 2(1): 15-42.
Dabbs, D. J. (2002). "Diagnostic immunohistochemistry." Philadelphia : Churchill Livingstone.
Dar, A. A., S. Majid, D. de Semir, M. Nosrati, V. Bezrookove and M. Kashani-Sabet (2011). "miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein." J Biol Chem 286(19): 16606-16614.
De Maziere, A. M., K. Muehlethaler, E. van Donselaar, S. Salvi, J. Davoust, J. C. Cerottini, F. Levy, J. W. Slot and D. Rimoldi (2002). "The melanocytic protein Melan-A/MART-1 has a subcellular localization distinct from typical melanosomal proteins." Traffic 3(9): 678-693.
Du, J., A. J. Miller, H. R. Widlund, M. A. Horstmann, S. Ramaswamy and D. E. Fisher (2003). "MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma." Am J Pathol 163(1): 333-343.
Fernando, S. S., S. Johnson and J. Bate (1994). "Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB-45 monoclonal antibody and NKI/C3 monoclonal antibody." Pathology 26(1): 16-19.
Granter, S. R., K. N. Weilbaecher, C. Quigley and D. E. Fisher (2002). "Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma." Appl Immunohistochem Mol Morphol 10(1): 47-51.
Gregory, P. A., A. G. Bert, E. L. Paterson, S. C. Barry, A. Tsykin, G. Farshid, M. A. Vadas, Y. Khew-Goodall and G. J. Goodall (2008). "The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1." Nat Cell Biol 10(5): 593-601.
Hanna, J. A., L. Hahn, S. Agarwal and D. L. Rimm (2012). "In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor microRNA." Lab Invest 92(10): 1390-1397.
Jungbluth, A. A., K. Iversen, K. Coplan, D. Kolb, E. Stockert, Y. T. Chen, L. J. Old and K. Busam (2000). "T311--an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues." Pathol Res Pract 196(4): 235-242.
Kasinski, A. L. and F. J. Slack (2011). "Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy." Nat Rev Cancer 11(12): 849-864.
Kaufman, C. K., C. Mosimann, Z. P. Fan, S. Yang, A. J. Thomas, J. Ablain, J. L. Tan, R. D. Fogley, E. van Rooijen, E. J. Hagedorn, C. Ciarlo, R. M. White, D. A. Matos, A. C. Puller, C. Santoriello, E. C. Liao, R. A. Young and L. I. Zon (2016). "A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation." Science 351(6272): aad2197.
Kaufmann, O., S. Koch, J. Burghardt, H. Audring and M. Dietel (1998). "Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections." Mod Pathol 11(8): 740-746.
Klinge, C. M. (2012). "miRNAs and estrogen action." Trends Endocrinol Metab 23(5): 223-233.
Korabiowska, M., U. Brinck, P. Middel, U. Brinkmann, H. Berger, H. J. Radzun, I. Ruschenburg and M. Droese (2000). "Proliferative activity in the progression of pigmented skin lesions, diagnostic and prognostic significance." Anticancer Res 20(3a): 1781-1785.
Ladstein, R. G., I. M. Bachmann, O. Straume and L. A. Akslen (2010). "Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma." BMC Cancer 10: 140.
Li, J., J. Z. Gao, J. L. Du, Z. X. Huang and L. X. Wei (2014). "Increased CDC20 expression is associated with development and progression of hepatocellular carcinoma." Int J Oncol 45(4): 1547-1555.
Li, L. X., K. A. Crotty, S. W. McCarthy, A. A. Palmer and J. J. Kril (2000). "A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions." Am J Dermatopathol 22(6): 489-495.
Liu, S. M., J. Lu, H. C. Lee, F. H. Chung and N. Ma (2014). "miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2." Oncotarget 5(19): 9444-9459.
M., B. S. S. a. H. (2000). "Morphological and immunophenotypic variations in malignant melanoma." Histopathology 36(5): 387-402.
Marzagalli, M., L. Casati, R. M. Moretti, M. Montagnani Marelli and P. Limonta (2015). "Estrogen Receptor beta Agonists Differentially Affect the Growth of Human Melanoma Cell Lines." PLoS One 10(7): e0134396.
Mazar, J., K. DeYoung, D. Khaitan, E. Meister, A. Almodovar, J. Goydos, A. Ray and R. J. Perera (2010). "The regulation of miRNA-211 expression and its role in melanoma cell invasiveness." PLoS One 5(11): e13779.
McKee, P. H., Calonje, E., Granter, S. R. (2005). " Pathology of the skinwith clinical correlations, 3rd ed." Philadel phia: Elsevier Mosby.
Michael, M. Z., O. C. SM, N. G. van Holst Pellekaan, G. P. Young and R. J. James (2003). "Reduced accumulation of specific microRNAs in colorectal neoplasia." Mol Cancer Res 1(12): 882-891.
Miettinen, M., M. Fernandez, K. Franssila, Z. Gatalica, J. Lasota and M. Sarlomo-Rikala (2001). "Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers." Am J Surg Pathol 25(2): 205-211.
Ohsie, S. J., G. P. Sarantopoulos, A. J. Cochran and S. W. Binder (2008). "Immunohistochemical characteristics of melanoma." J Cutan Pathol 35(5): 433-444.
Orchard, G. E. (2000). "Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma." Histochem J 32(8): 475-481.
Ordonez, N. G., X. L. Ji and R. C. Hickey (1988). "Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma." Am J Clin Pathol 90(4): 385-390.
Orouji, E., A. Orouji, T. Gaiser, L. Larribere, C. Gebhardt and J. Utikal (2016). "MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma." Int J Cancer 138(9): 2257-2262.
Porkka, K. P., M. J. Pfeiffer, K. K. Waltering, R. L. Vessella, T. L. Tammela and T. Visakorpi (2007). "MicroRNA expression profiling in prostate cancer." Cancer Res 67(13): 6130-6135.
Pritchard, C. C., H. H. Cheng and M. Tewari (2012). "MicroRNA profiling: approaches and considerations." Nat Rev Genet 13(5): 358-369.
Qureshi, A. and S. Pervez (2010). "Allred scoring for ER reporting and it′s impact in clearly distinguishing ER negative from ER positive breast cancers." J Pak Med Assoc 60(5): 350-353.
Rieger, E., R. Hofmann-Wellenhof, H. P. Soyer, R. Kofler, L. Cerroni, J. Smolle and H. Kerl (1993). "Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study." J Cutan Pathol 20(3): 229-236.
Roh, M. R., P. Eliades, S. Gupta and H. Tsao (2015). "Cutaneous Melanoma in Women." Int J Womens Dermatol 1(1): 21-25.
Schadendorf, D., D. E. Fisher, C. Garbe, J. E. Gershenwald, J. J. Grob, A. Halpern, M. Herlyn, M. A. Marchetti, G. McArthur, A. Ribas, A. Roesch and A. Hauschild (2015). "Melanoma." Nat Rev Dis Primers 1: 15003.
Scholzen, T. and J. Gerdes (2000). "The Ki-67 protein: from the known and the unknown." J Cell Physiol 182(3): 311-322.
Shen, H. and W. Wu (2015). "Study of melanin bleaching after immunohistochemistry of melanin-containing tissues." Appl Immunohistochem Mol Morphol 23(4): 303-307.
Siegfried, J. M., P. A. Hershberger and L. P. Stabile (2009). "Estrogen receptor signaling in lung cancer." Semin Oncol 36(6): 524-531.
Specht, E., D. Kaemmerer, J. Sanger, R. M. Wirtz, S. Schulz and A. Lupp (2015). "Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms." Histopathology 67(3): 368-377.
Sundram, U., J. D. Harvell, R. V. Rouse and Y. Natkunam (2003). "Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA." Mod Pathol 16(8): 802-810.
Trefzer, U., N. Rietz, Y. Chen, H. Audring, G. Herberth, P. Siegel, S. Reinke, P. Koniger, S. Wu, J. Ma, Y. Liu, H. Wang, W. Sterry and Y. Guo (2000). "SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions." Arch Dermatol Res 292(12): 583-589.
Uguen, A., M. Talagas, S. Costa, S. Duigou, S. Bouvier, M. De Braekeleer and P. Marcorelles (2015). "A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma." Diagn Pathol 10: 195.
Vogt, T., K. H. Zipperer, A. Vogt, D. Holzel, M. Landthaler and W. Stolz (1997). "p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin." Histopathology 30(1): 57-63.
Volinia, S., G. A. Calin, C. G. Liu, S. Ambs, A. Cimmino, F. Petrocca, R. Visone, M. Iorio, C. Roldo, M. Ferracin, R. L. Prueitt, N. Yanaihara, G. Lanza, A. Scarpa, A. Vecchione, M. Negrini, C. C. Harris and C. M. Croce (2006). "A microRNA expression signature of human solid tumors defines cancer gene targets." Proc Natl Acad Sci U S A 103(7): 2257-2261.
Weinstein, D., J. Leininger, C. Hamby and B. Safai (2014). "Diagnostic and prognostic biomarkers in melanoma." J Clin Aesthet Dermatol 7(6): 13-24.
Wick, M. R., P. E. Swanson and A. Rocamora (1988). "Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors." J Cutan Pathol 15(4): 201-207.
Wu, C. E., C. H. Hsieh, C. J. Chang, J. T. Yeh, T. T. Kuo, C. H. Yang, Y. F. Lo, K. J. Lin, Y. C. Lin and J. W. Chang (2015). "Prognostic factors for Taiwanese patients with cutaneous melanoma undergoing sentinel lymph node biopsy." J Formos Med Assoc 114(5): 415-421.
Yanaihara, N., N. Caplen, E. Bowman, M. Seike, K. Kumamoto, M. Yi, R. M. Stephens, A. Okamoto, J. Yokota, T. Tanaka, G. A. Calin, C. G. Liu, C. M. Croce and C. C. Harris (2006). "Unique microRNA molecular profiles in lung cancer diagnosis and prognosis." Cancer Cell 9(3): 189-198.
Yi-Ju Chen, C.-Y. W., Jung-Ta Chen,Jui-Lung Shen, Chien-Chou Chen, and Hsi-Ching Wang (1999). "Clinicopathologic analysis of malignant melanoma in Taiwan." J Am Acad Dermatol 41: 945-949.
Yi, R. and E. Fuchs (2010). "MicroRNA-mediated control in the skin." Cell Death Differ 17(2): 229-235.
Zubovits, J., E. Buzney, L. Yu and L. M. Duncan (2004). "HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma." Hum Pathol 35(2): 217-223. |
[Endnote RIS 格式]
[相關文章]
[文章引用]
[完整記錄]
[館藏目錄]
[檢視]
plurk
funp
live
udn
HD
myshare
netvibes
friend
youpush
delicious
baidu
Google bookmarks
del.icio.us
hemidemi
facebook
twitter
google
reddit